Relevant disclosures attached

Pat Growth 25pctEbitda Margin ExpansionEmphasis Of MatterRelated Party TransactionsDebt Equity ThresholdResults View source PDF

FORTIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+0.5%1-day move

₹961.90

prior close

₹969.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.6+1.3+1.5+0.9+0.5+0.0-2.6-3.4-3.0-2.2+0.8-0.9-2.0—

Up moveDown movePending

AI summary

Fortis Healthcare Limited reported strong FY2026 consolidated results with revenue from operations at ₹9,12,784 lakhs (up 17.3% from ₹7,78,275 lakhs). EBITDA grew 29% to ₹2,13,564 lakhs while net profit increased 31.5% to ₹1,06,419 lakhs. EPS stands at ₹13.80 per share. The Board recommended a final dividend of ₹1 per equity share. Statutory auditors B S R & Co. LLP issued an unmodified opinion. However, the auditor's report includes two Emphasis of Matter notes: (1) Ongoing SFIO investigation regarding alleged improper transactions and non-compliances dating back to events prior to 2018, with the Group having recorded provisions and launched legal proceedings against erstwhile promoters; (2) Supreme Court order directing forensic audit of transactions with RHT Health Trust. Exceptional items showed a net loss of ₹2,224 lakhs.

Likely market impact

Strong financial performance with 31.5% PAT growth and margin expansion. However, historical regulatory issues (SFIO investigation, Supreme Court observation on RHT transactions) remain as risk factors requiring shareholder attention.